Emtricitabine and Tenofovir alafenamide Atlanta Medicare Dosage/Direction for Use

Therapy should be initiated by a physician experienced in the management of HIV infection.
Posology: Adults and adolescents aged 12 years and older, weighing at least 35 kg: Emtricitabine and tenofovir alafenamide fumarate should be administered as shown in Table 5. (See Table 5.)

Click on icon to see table/diagram/image

If the patient misses a dose of Emtricitabine and tenofovir alafenamide fumarate within 18 hours of the time it is usually taken, the patient should take Emtricitabine and tenofovir alafenamide fumarate as soon as possible and resume the normal dosing schedule. If a patient misses a dose of Emtricitabine and tenofovir alafenamide fumarate by more than 18 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.
If the patient vomits within 1 hour of taking Emtricitabine and tenofovir alafenamide fumarate another tablet should be taken.
Elderly: No dose adjustment of Emtricitabine and tenofovir alafenamide fumarate is required in elderly patients (see Pharmacology: Pharmacodynamics and Pharmacokinetics under Actions).
Renal impairment: No dose adjustment of Emtricitabine and tenofovir alafenamide fumarate is required in adults or adolescents (aged at least 12 years and of at least 35 kg body weight) with estimated creatinine clearance (CrCl) ≥30 mL/min.
Emtricitabine and tenofovir alafenamide fumarate should be discontinued in patients with estimated CrCl that declines below 30 mL/min during treatment (see Pharmacology: Pharmacokinetics under Actions).
No dose adjustment of emtricitabine and tenofovir alafenamide fumarate is required in adults with end stage renal disease (estimated CrCl <15 mL/min) on chronic haemodialysis; however, emtricitabine and tenofovir alafenamide fumarate should generally be avoided but may be used in these patients if the potential benefits are considered to outweigh the potential risks (see Precautions and Pharmacology: Pharmacokinetics under Actions). On days of haemodialysis, emtricitabine and tenofovir alafenamide fumarate should be administered after completion of haemodialysis treatment.
Emtricitabine and tenofovir alafenamide fumarate should be avoided in patients with estimated CrCl ≥15 mL/min and <30 mL/min, or <15 mL/min who are not on chronic haemodialysis, as safety of emtricitabine and tenofovir alafenamide fumarate has not been established in these populations.
No data are available to make dose recommendations in children less than 18 years with end stage renal disease.
Hepatic impairment: No dose adjustment of Emtricitabine and tenofovir alafenamide fumarate is required in patients with hepatic impairment.
Paediatric population: The safety and efficacy of Emtricitabine and tenofovir alafenamide fumarate in children younger than 12 years of age, or weighing <35 kg, have not yet been established. No data are available.
Method of administration: Emtricitabine and tenofovir alafenamide fumarate should be taken orally, once daily with or without food (see Pharmacology: Pharmacokinetics under Actions). The film-coated tablet should not be chewed, crushed, or split.